Cargando…
IL-10 Signaling Elicited by Nivolumab-Induced Activation of the MAP Kinase Pathway Does Not Fully Contribute to Nivolumab-Modulated Heterogeneous T Cell Responses
Immune checkpoint inhibitor (ICI) therapy has revolutionized anti-cancer treatment for many late-stage cancer patients. However, ICI therapy has thus far demonstrated limited efficacy for most patients, and it remains unclear why this is so. Interleukin 10 (IL-10) is a cytokine that has been recogni...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8584131/ https://www.ncbi.nlm.nih.gov/pubmed/34769278 http://dx.doi.org/10.3390/ijms222111848 |
_version_ | 1784597373124608000 |
---|---|
author | Harper, Taylor A. Bacot, Silvia M. Fennell, Christie Jane Matthews, Rebecca L. Zhu, Christina Yue, Peng Benton, Alexander Friedman, Devira Akue, Adovi KuKuruga, Mark A. Lee, Shiowjen Wang, Tao Feldman, Gerald M. |
author_facet | Harper, Taylor A. Bacot, Silvia M. Fennell, Christie Jane Matthews, Rebecca L. Zhu, Christina Yue, Peng Benton, Alexander Friedman, Devira Akue, Adovi KuKuruga, Mark A. Lee, Shiowjen Wang, Tao Feldman, Gerald M. |
author_sort | Harper, Taylor A. |
collection | PubMed |
description | Immune checkpoint inhibitor (ICI) therapy has revolutionized anti-cancer treatment for many late-stage cancer patients. However, ICI therapy has thus far demonstrated limited efficacy for most patients, and it remains unclear why this is so. Interleukin 10 (IL-10) is a cytokine that has been recognized as a central player in cancer biology with its ability to inhibit anti-tumor T cell responses. Recent studies suggest that IL-10 might also exert some intrinsic anti-tumor T cell responses, and clinical studies using recombinant IL-10 alone or in combination with ICI are underway. This paradoxical effect of IL-10 and its underlying mechanisms impacting ICI-modulated T cell responses remain poorly understood. In this study, using an in vitro mixed lymphocyte reaction assay, we found that treatment with ICIs such as the anti-programmed cell death receptor-1 (PD-1) mAb nivolumab elicits a strong expression of IL-10. While neutralization of IL-10 signaling with an anti-IL-10 specific mAb significantly decreases the production of IFN-γ by T cells in a cohort of donor cells, the opposite effect was observed in other donor cells. Similarly, neutralization of IL-10 signaling significantly decreases the expression of T cell activation markers Ki67 and CD25, as well as the production of Granzyme B in a cohort of donor cells, whereas the opposite effect was observed in others. Furthermore, we found that nivolumab and IL-10 differentially modulate the signal transducer and activator of transcription 3 (STAT3) and AKT serine–threonine kinase pathways. Finally, we found that nivolumab activates the mitogen-activated protein kinase (MAPK) pathway, which in turn is responsible for the observed induction of IL-10 production by nivolumab. These findings provide new insights into the mechanisms underlying anti-PD-1-modulated T cell responses by IL-10, which could lead to the discovery of novel combination treatments that target IL-10 and immune checkpoint molecules. |
format | Online Article Text |
id | pubmed-8584131 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-85841312021-11-12 IL-10 Signaling Elicited by Nivolumab-Induced Activation of the MAP Kinase Pathway Does Not Fully Contribute to Nivolumab-Modulated Heterogeneous T Cell Responses Harper, Taylor A. Bacot, Silvia M. Fennell, Christie Jane Matthews, Rebecca L. Zhu, Christina Yue, Peng Benton, Alexander Friedman, Devira Akue, Adovi KuKuruga, Mark A. Lee, Shiowjen Wang, Tao Feldman, Gerald M. Int J Mol Sci Article Immune checkpoint inhibitor (ICI) therapy has revolutionized anti-cancer treatment for many late-stage cancer patients. However, ICI therapy has thus far demonstrated limited efficacy for most patients, and it remains unclear why this is so. Interleukin 10 (IL-10) is a cytokine that has been recognized as a central player in cancer biology with its ability to inhibit anti-tumor T cell responses. Recent studies suggest that IL-10 might also exert some intrinsic anti-tumor T cell responses, and clinical studies using recombinant IL-10 alone or in combination with ICI are underway. This paradoxical effect of IL-10 and its underlying mechanisms impacting ICI-modulated T cell responses remain poorly understood. In this study, using an in vitro mixed lymphocyte reaction assay, we found that treatment with ICIs such as the anti-programmed cell death receptor-1 (PD-1) mAb nivolumab elicits a strong expression of IL-10. While neutralization of IL-10 signaling with an anti-IL-10 specific mAb significantly decreases the production of IFN-γ by T cells in a cohort of donor cells, the opposite effect was observed in other donor cells. Similarly, neutralization of IL-10 signaling significantly decreases the expression of T cell activation markers Ki67 and CD25, as well as the production of Granzyme B in a cohort of donor cells, whereas the opposite effect was observed in others. Furthermore, we found that nivolumab and IL-10 differentially modulate the signal transducer and activator of transcription 3 (STAT3) and AKT serine–threonine kinase pathways. Finally, we found that nivolumab activates the mitogen-activated protein kinase (MAPK) pathway, which in turn is responsible for the observed induction of IL-10 production by nivolumab. These findings provide new insights into the mechanisms underlying anti-PD-1-modulated T cell responses by IL-10, which could lead to the discovery of novel combination treatments that target IL-10 and immune checkpoint molecules. MDPI 2021-10-31 /pmc/articles/PMC8584131/ /pubmed/34769278 http://dx.doi.org/10.3390/ijms222111848 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Harper, Taylor A. Bacot, Silvia M. Fennell, Christie Jane Matthews, Rebecca L. Zhu, Christina Yue, Peng Benton, Alexander Friedman, Devira Akue, Adovi KuKuruga, Mark A. Lee, Shiowjen Wang, Tao Feldman, Gerald M. IL-10 Signaling Elicited by Nivolumab-Induced Activation of the MAP Kinase Pathway Does Not Fully Contribute to Nivolumab-Modulated Heterogeneous T Cell Responses |
title | IL-10 Signaling Elicited by Nivolumab-Induced Activation of the MAP Kinase Pathway Does Not Fully Contribute to Nivolumab-Modulated Heterogeneous T Cell Responses |
title_full | IL-10 Signaling Elicited by Nivolumab-Induced Activation of the MAP Kinase Pathway Does Not Fully Contribute to Nivolumab-Modulated Heterogeneous T Cell Responses |
title_fullStr | IL-10 Signaling Elicited by Nivolumab-Induced Activation of the MAP Kinase Pathway Does Not Fully Contribute to Nivolumab-Modulated Heterogeneous T Cell Responses |
title_full_unstemmed | IL-10 Signaling Elicited by Nivolumab-Induced Activation of the MAP Kinase Pathway Does Not Fully Contribute to Nivolumab-Modulated Heterogeneous T Cell Responses |
title_short | IL-10 Signaling Elicited by Nivolumab-Induced Activation of the MAP Kinase Pathway Does Not Fully Contribute to Nivolumab-Modulated Heterogeneous T Cell Responses |
title_sort | il-10 signaling elicited by nivolumab-induced activation of the map kinase pathway does not fully contribute to nivolumab-modulated heterogeneous t cell responses |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8584131/ https://www.ncbi.nlm.nih.gov/pubmed/34769278 http://dx.doi.org/10.3390/ijms222111848 |
work_keys_str_mv | AT harpertaylora il10signalingelicitedbynivolumabinducedactivationofthemapkinasepathwaydoesnotfullycontributetonivolumabmodulatedheterogeneoustcellresponses AT bacotsilviam il10signalingelicitedbynivolumabinducedactivationofthemapkinasepathwaydoesnotfullycontributetonivolumabmodulatedheterogeneoustcellresponses AT fennellchristiejane il10signalingelicitedbynivolumabinducedactivationofthemapkinasepathwaydoesnotfullycontributetonivolumabmodulatedheterogeneoustcellresponses AT matthewsrebeccal il10signalingelicitedbynivolumabinducedactivationofthemapkinasepathwaydoesnotfullycontributetonivolumabmodulatedheterogeneoustcellresponses AT zhuchristina il10signalingelicitedbynivolumabinducedactivationofthemapkinasepathwaydoesnotfullycontributetonivolumabmodulatedheterogeneoustcellresponses AT yuepeng il10signalingelicitedbynivolumabinducedactivationofthemapkinasepathwaydoesnotfullycontributetonivolumabmodulatedheterogeneoustcellresponses AT bentonalexander il10signalingelicitedbynivolumabinducedactivationofthemapkinasepathwaydoesnotfullycontributetonivolumabmodulatedheterogeneoustcellresponses AT friedmandevira il10signalingelicitedbynivolumabinducedactivationofthemapkinasepathwaydoesnotfullycontributetonivolumabmodulatedheterogeneoustcellresponses AT akueadovi il10signalingelicitedbynivolumabinducedactivationofthemapkinasepathwaydoesnotfullycontributetonivolumabmodulatedheterogeneoustcellresponses AT kukurugamarka il10signalingelicitedbynivolumabinducedactivationofthemapkinasepathwaydoesnotfullycontributetonivolumabmodulatedheterogeneoustcellresponses AT leeshiowjen il10signalingelicitedbynivolumabinducedactivationofthemapkinasepathwaydoesnotfullycontributetonivolumabmodulatedheterogeneoustcellresponses AT wangtao il10signalingelicitedbynivolumabinducedactivationofthemapkinasepathwaydoesnotfullycontributetonivolumabmodulatedheterogeneoustcellresponses AT feldmangeraldm il10signalingelicitedbynivolumabinducedactivationofthemapkinasepathwaydoesnotfullycontributetonivolumabmodulatedheterogeneoustcellresponses |